On Tuesday, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) revealed topline results from the relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML) cohort in the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib.
The cohort met the primary endpoint with a complete remission (CR) plus CR with a partial hematological recovery (CRh) rate of 23% among the efficacy evaluable adults.
Among the patients who achieved CR/CRh, 12 had a CR, and three had a CRh.
At the data cutoff, the observed median duration of CR/CRh responses was 4.7 months, with three patients remaining in response.
Minimal residual disease (MRD) status was assessed in 14 of 15 patients who achieved CR/CRh, 64% (9/14) of whom were MRD negative. The overall response rate (ORR) was 47%.
17% of patients who achieved an overall response underwent hematopoietic stem cell transplant (HSCT) following treatment with revumenib, with three resuming revumenib therapy post-transplant.
The safety population included 84 adult and pediatric patients with R/R mNPM1 AML in the Phase 2 portion of the AUGMENT-101 trial.
The safety profile observed with revumenib in this population was consistent with previously reported data.
Treatment-related adverse events (TRAEs) leading to treatment discontinuations were 5%
The company is conducting several trials of revumenib across the treatment landscape in mNPM1 and KMT2A-rearranged (KMT2Ar) acute leukemias.
Syndax expects to achieve the following upcoming revumenib milestones:
Price Action: SNDX stock is down 22.1% at $16.96 at last check Tuesday.
Read Next:
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
